Physician profile
John L Lin
NPI 1194756981
$1,155.07
in general payments reported to CMS, 2019-2025
12 companies · $56.97 in 2025
The $56.97 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.79 · 2021: $12.61 · 2022: $42.51 · 2023: $80.57 · 2024: $890 · 2025: $56.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $690 · Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $689.72 |
| Food and Beverage | $337.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $755.71 | 2024 | Iovera, Zilretta, Exparel |
| Abbvie INC. | $142.73 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $45.77 | 2023-2024 | Recarbrio, Zerbaxa, Dificid |
| Genzyme Corporation | $33.59 | 2024 | |
| Amgen INC. | $28.82 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.93 | 2024 | Ultomiris |
| Merz Pharmaceuticals, LLC | $25.68 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $23.43 | 2024 | Caldolor |
| Novartis Pharmaceuticals Corporation | $22.45 | 2019 | |
| Portola Pharmaceuticals, LLC | $21.52 | 2019 | |
| Hollister Incorporated | $16.83 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.